Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

1.

Protective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction.

Czikora I, Sridhar S, Gorshkov B, Alieva IB, Kasa A, Gonzales J, Potapenko O, Umapathy NS, Pillich H, Rick FG, Block NL, Verin AD, Chakraborty T, Matthay MA, Schally AV, Lucas R.

Front Physiol. 2014 Jul 15;5:259. doi: 10.3389/fphys.2014.00259. eCollection 2014.

PMID:
25076911
[PubMed]
Free PMC Article
3.

Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.

Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV.

World J Gastroenterol. 2014 May 28;20(20):6102-12. doi: 10.3748/wjg.v20.i20.6102.

PMID:
24876732
[PubMed - in process]
Free PMC Article
4.

Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.

Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1084-9. doi: 10.1073/pnas.1323102111. Epub 2014 Jan 6.

PMID:
24395797
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists.

Jaszberenyi M, Rick FG, Popovics P, Block NL, Zarandi M, Cai RZ, Vidaurre I, Szalontay L, Jayakumar AR, Schally AV.

Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):781-6. doi: 10.1073/pnas.1322622111. Epub 2013 Dec 30.

PMID:
24379381
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities.

Cai R, Schally AV, Cui T, Szalontay L, Halmos G, Sha W, Kovacs M, Jaszberenyi M, He J, Rick FG, Popovics P, Kanashiro-Takeuchi R, Hare JM, Block NL, Zarandi M.

Peptides. 2014 Feb;52:104-12. doi: 10.1016/j.peptides.2013.12.010. Epub 2013 Dec 25.

PMID:
24373935
[PubMed - in process]
7.

Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch.

Tennakoon JB, Shi Y, Han JJ, Tsouko E, White MA, Burns AR, Zhang A, Xia X, Ilkayeva OR, Xin L, Ittmann MM, Rick FG, Schally AV, Frigo DE.

Oncogene. 2013 Nov 4. doi: 10.1038/onc.2013.463. [Epub ahead of print]

PMID:
24186207
[PubMed - as supplied by publisher]
8.

Agonists of luteinizing hormone-releasing hormone in prostate cancer.

Rick FG, Block NL, Schally AV.

Expert Opin Pharmacother. 2013 Nov;14(16):2237-47. doi: 10.1517/14656566.2013.834328. Epub 2013 Aug 28. Review.

PMID:
23984804
[PubMed - indexed for MEDLINE]
9.

Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs.

Lucas R, Czikora I, Sridhar S, Zemskov E, Gorshkov B, Siddaramappa U, Oseghale A, Lawson J, Verin A, Rick FG, Block NL, Pillich H, Romero M, Leustik M, Schally AV, Chakraborty T.

Toxins (Basel). 2013 Jul 15;5(7):1244-60. doi: 10.3390/toxins5071244. Review.

PMID:
23860351
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.

Szepeshazi K, Schally AV, Block NL, Halmos G, Nadji M, Szalontay L, Vidaurre I, Abi-Chaker A, Rick FG.

Oncotarget. 2013 May;4(5):751-60.

PMID:
23744510
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.

Seitz S, Rick FG, Schally AV, Treszl A, Hohla F, Szalontay L, Zarandi M, Ortmann O, Engel JB, Buchholz S.

Oncol Rep. 2013 Jul;30(1):413-8. doi: 10.3892/or.2013.2435. Epub 2013 Apr 29.

PMID:
23624870
[PubMed - indexed for MEDLINE]
12.

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.

Rick FG, Block NL, Schally AV.

Onco Targets Ther. 2013 Apr 16;6:391-402. doi: 10.2147/OTT.S32426. Print 2013.

PMID:
23620672
[PubMed]
Free PMC Article
13.

Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

Jaszberenyi M, Schally AV, Block NL, Nadji M, Vidaurre I, Szalontay L, Rick FG.

Oncotarget. 2013 Mar;4(3):422-32.

PMID:
23518876
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro.

Jaszberenyi M, Schally AV, Block NL, Zarandi M, Cai RZ, Vidaurre I, Szalontay L, Jayakumar AR, Rick FG.

Target Oncol. 2013 Dec;8(4):281-90. doi: 10.1007/s11523-013-0264-y. Epub 2013 Feb 1.

PMID:
23371031
[PubMed - indexed for MEDLINE]
15.

Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.

Rick FG, Abi-Chaker A, Szalontay L, Perez R, Jaszberenyi M, Jayakumar AR, Shamaladevi N, Szepeshazi K, Vidaurre I, Halmos G, Krishan A, Block NL, Schally AV.

Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2617-22. doi: 10.1073/pnas.1222355110. Epub 2013 Jan 28.

PMID:
23359692
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.

Rick FG, Schally AV, Block NL, Abi-Chaker A, Krishan A, Szalontay L.

Prostate. 2013 Jun;73(8):873-83. doi: 10.1002/pros.22633. Epub 2012 Dec 31.

PMID:
23280565
[PubMed - indexed for MEDLINE]
17.

Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease.

Jaszberenyi M, Rick FG, Szalontay L, Block NL, Zarandi M, Cai RZ, Schally AV.

Aging (Albany NY). 2012 Nov;4(11):755-67.

PMID:
23211425
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Hormonal manipulation of benign prostatic hyperplasia.

Rick FG, Saadat SH, Szalontay L, Block NL, Kazzazi A, Djavan B, Schally AV.

Curr Opin Urol. 2013 Jan;23(1):17-24. doi: 10.1097/MOU.0b013e32835abd18. Review.

PMID:
23202285
[PubMed - indexed for MEDLINE]
19.

Re: editorial comment on LHRH antagonist cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia (Prostate 2011; 71: 736-747).

Rick FG, Block NL, Schally AV.

J Urol. 2013 Apr;189(4):1604-5. doi: 10.1016/j.juro.2012.10.062. Epub 2012 Oct 24. No abstract available.

PMID:
23103799
[PubMed]
20.

GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.

Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Buchholz S, Block NL, Hohla F.

Cell Cycle. 2012 Nov 15;11(22):4203-10. doi: 10.4161/cc.22498. Epub 2012 Oct 24.

PMID:
23095641
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk